Key facts
- It has raised $1.0M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Sep 2025.
- Notable investors include MassChallenge, Venture Development Center (Massachusetts), National Center For Advancing Translational Sciences.
- Factor Bioscience has filed 1 Form D with the SEC, most recently Sep 2025 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Factor Bioscience
Funding rounds
1 roundsAbout Factor Bioscience
Developer of gene expression and cell fate technology platform designed to advance the study and treatment of diseases. The company's platform specializes in reprogramming somatic cells to a pluripotent stem-cell state, enabling clients to produce patient-specific cells for transplantation that have wide-ranging applications in personalized regenerative medicine.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2011
- Employees
- 13
- Website
- factor.bio/
- Ownership
- Privately Held (backing)
Factor Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Factor Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Factor Bioscience in its N-PORT filings yet. We sweep new filings monthly.